Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)
Status:
Enrolling by invitation
Trial end date:
2024-06-13
Target enrollment:
Participant gender:
Summary
The primary objective of this proposal is to conduct an early Phase 2 clinical trial to
determine the acceptability, dosing, tolerability and safety of mirtazapine for severe nausea
and vomiting of pregnancy (sNVP) that is not adequately responsive to current standard
treatments. This plan mirrors clinical practice since commonly prescribed antiemetic/
antinauseant drugs will be tested for efficacy before treating with mirtazapine.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)